AORT at a glance
ARTIVION, INC. (AORT, SEC CIK 784199) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ARTIVION, INC. (AORT) reported revenue of $441.3 million (up 13.6% from FY2024) and net income of $9.8 million. Diluted EPS was $0.21.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding ARTIVION, INC. (AORT) shares worth $493.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by GREEN ANDREW M on September 10, 2026 of 11,480 shares at $24.97 per share.
- In the last 90 days, AORT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($2.6M) on Form 4, a net sale of $2.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $441.3M
- +13.6% vs prior year
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$2.6M
- 13F holders
- 30 funds
- $493.5M · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Manufacturer and distributor of medical devices and implantable human tissues for cardiac and vascular surgery, focusing on aortic disease treatment
- New product launch: Arcevo™ LSA Hybrid Stent Graft System introduced in EMEA and APAC in 2025, with US PMA trial ongoing, plus PerClot® hemostatic powder manufacturing started Q2 2023
- Strategic shift: Expanded global reach with new international markets including China and Brazil, enhanced pipeline with next-generation devices like Arcevo LSA and NEO EDE custom version
- Quantitative metric: FDA granted humanitarian device exemption for AMDS hybrid prosthesis in Dec 2024 enabling limited US commercial distribution before full PMA approval expected in 2026
- Noteworthy fact: CMS created a new unique DRG procedure code for AMDS effective Oct 1, 2025, reflecting recognition of its distinct hospital resource use for complex aortic arch repair
Risk Factors
- Regulatory risk: Italian medical device overpayment repayment exposure $2.3M for 2019–2025 period under Ministerial Decree, potential further government assessment
- Geopolitical risk: NEXUS products solely made in Israel amid Middle East conflicts, risking supply disruption from war, sanctions, or export controls
- Operational risk: Single-source suppliers for BioGlue components and On-X grafts could halt manufacturing if suppliers face issues, risking product availability
- Competitive risk: Facing competition from Baxter, J&J’s Ethicon, Medtronic, Abbott with greater resources and stronger regulatory approval track records
- Financial risk: Acquisition-related impairments including Endospan loan and option write-downs affecting market value and risking future goodwill impairments
Management Discussion & Analysis
- Revenue $441.3M in 2025, up 14% YoY from $388.5M in 2024; constant currency increase 13%
- Gross margin 64% in 2025, flat YoY despite 14% gross margin dollar growth to $284.2M
- Best segment: Aortic stent grafts $159.4M +29% YoY; Worst: Preservation services $95.5M -3% YoY
- Operating expenses increased 25% to $226.5M driven by sales/marketing and cybersecurity costs; R&D up 9% to $31.0M
- Cash & equivalents $64.9M at year-end; $220M nominal debt outstanding; no specific buyback or dividend data given
- Management notes ongoing seasonality, cybersecurity incident impacts in 2024; AMDS product commercial launch in US anticipated in 2026
AI summary of the AORT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $125.8M, up 11% YoY from $113.0M; constant-currency growth 9%
- Gross margin 64% vs 65% YoY; G&A and marketing 63% of revenue vs 51%
- Best performer: On-X revenue $30.5M, up 19%; worst: surgical sealants $19.3M, flat
- Product revenue $99.9M, up 14%; aortic stent grafts $46.4M, up 16%
- Near-term headwinds: seasonal third-quarter demand declines and foreign-exchange volatility
Risk Factors
- Newly triggered geopolitical supply risk: Endospan acquisition completed May 18, 2026, adding sole-source NEXUS manufacturing in Herzliya, Israel
- Regulatory risk: Italian government assessing 2019–2024 medical-device repayments, with estimated 2019–2025 exposure of approximately $2.3 million
- Tissue-preservation compliance risk: FDA draft tuberculosis guidance could significantly reduce safe implantable human-tissue supply if implemented
- Competitive risk: GLP-1 drugs may create investor and customer confusion and pressure perceived product demand
- Currency risk: Most foreign revenues denominated in Euros, exposing revenue and margins to exchange-rate fluctuations
AI summary of the AORT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 references Exhibit 99.1 for Artivion’s fiscal 2026 results and accompanying press release
- Forward-looking statements subject to material execution risks and potential deviation from management expectations
Item EX-99.1: Item EX-99.1
- Q2 revenue $125.8M, up 11% GAAP and 9% constant currency, led by On-X growth 18% and stent graft growth 12%
- GAAP net loss $(13.5)M, or $(0.28) per share, versus $1.3M profit; non-GAAP EPS declined to $0.13 from $0.24
Item 7.01: Regulation FD Disclosure
- Artivion completed its acquisition of Endospan, an Israeli aortic-device developer
- Endospan’s Nexus™ product expands Artivion’s portfolio for treating aortic instability
Item 8.01: Other Events
- Endospan acquisition closed May 18, 2026, adding its NEXUS™ Aortic Arch Stent Graft System to Artivion’s portfolio
- Net cash purchase price approximately $131.3 million after offsetting intercompany loans
Item 5.07: Submission of Matters to a Vote of Security Holders
- All nine director nominees elected, supporting continuity of Artivion’s board leadership
- Executive compensation approved in non-binding vote, with 36,876,134 votes for and 2,291,059 against
AI summaries of AORT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AORT
Don't miss the next AORT filing
- Alerts as it files. A push when AORT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AORT, by share count.
- Ask anything. An AI agent that reads every AORT filing and answers with sources.
AORT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| GREEN ANDREW M | Sell | Sep 10, 2026 | 11,480 | $24.97 |
| GREEN ANDREW M | Sell | Sep 3, 2026 | 1,493 | $26.02 |
| GREEN ANDREW M | Sell | Sep 2, 2026 | 6,510 | $27.27 |
| Mackin James P | Sell | Aug 19, 2026 | 70,000 | $28.95 |
| GREEN ANDREW M | Sell | Aug 14, 2026 | 616 | $28.55 |
| Berry Lance A | Sell | Aug 14, 2026 | 715 | $28.55 |
| Holloway Jean F | Sell | Aug 12, 2026 | 977 | $28.49 |
| GREEN ANDREW M | M | Jun 11, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $388.5M | $441.3M |
| Gross Profit | - | $248.8M | $284.2M |
| Operating Income | - | $38.9M | $33.7M |
| Net Income | - | -$13.4M | $9.8M |
| Gross Margin | - | 64.0% | 64.4% |
| Op. Margin | - | 10.0% | 7.6% |
| Net Margin | - | -3.4% | 2.2% |
| Balance Sheet | |||
| Total Assets | $792.4M | $789.1M | $884.8M |
| Equity | $281.8M | $276.2M | $448.2M |
| ROE | - | -4.8% | 2.2% |
| Per Share | |||
| EPS | - | $-0.32 | $0.21 |
| Cash Flow | |||
| Operating CF | - | $22.2M | $39.9M |
| CapEx | - | $11.2M | $39.0M |
Source: XBRL data in ARTIVION, INC. (AORT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AORT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $493.5M |
| Q1 2026 | 29 | $758.2M |
| Q4 2025 | 28 | $961.7M |
| Q3 2025 | 28 | $852.6M |
| Q2 2025 | 28 | $590.9M |
| Q1 2025 | 25 | $327.2M |
| Q4 2024 | 20 | $247.8M |
| Q3 2024 | 18 | $124.8M |
- Citadel Advisors LLC+756.7K (+1068%)
- D.E. Shaw & Co+431.7K (+6615%)
- Morgan Stanley+288.7K (+13%)
- BlackRock+199.2K (+3%)
- State Street Corp+175.8K (+10%)
- FMR LLC (Fidelity)−620.0K (-24%)
- Two Sigma Investments−338.6K (-47%)
- Dimensional Fund Advisors−79.6K (-8%)
- Vanguard Portfolio Management LLC−49.2K (-5%)
- U.S. Bancorp−18.3K (-97%)
- Renaissance Technologies LLC+67.8K
- Allstate+21.5K
- HANCOCK WHITNEY CORP+11.1K
- Marex Group plc−18.0K
- Truist Financial−9.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AORT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 8-K | May 15, 2026 | - | Analysis | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
AORT SEC filings: frequently asked questions
Are AORT insiders buying or selling?
In the last 90 days, ARTIVION, INC. (AORT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $2.6 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AORT stock?
As of June 30, 2026, the largest ARTIVION, INC. (AORT) holders among the 13F filers tracked by SignalX were BlackRock ($150.0 million), Morgan Stanley ($57.5 million), Vanguard Capital Management LLC ($45.0 million), FMR LLC (Fidelity) ($44.1 million), State Street Corp ($41.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AORT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ARTIVION, INC. (AORT) reported revenue of $441.3 million (up 13.6% from FY2024) and net income of $9.8 million. Diluted EPS was $0.21. The figures come from the XBRL data in the 10-K.
What are the main risks in AORT's latest 10-K?
In the 10-K filed February 18, 2026, ARTIVION, INC. (AORT) flagged: Regulatory risk: Italian medical device overpayment repayment exposure $2.3M for 2019–2025 period under Ministerial Decree, potential further government assessment. Geopolitical risk: NEXUS products solely made in Israel amid Middle East conflicts, risking supply disruption from war, sanctions, or export controls. (AI summary of the Risk Factors section.)
What did AORT report in its latest 8-K?
ARTIVION, INC. (AORT) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 references Exhibit 99.1 for Artivion’s fiscal 2026 results and accompanying press release.
What are the latest AORT SEC filings?
ARTIVION, INC. (AORT) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 11, 2026.
What is AORT's SEC CIK number?
ARTIVION, INC. (AORT)'s SEC Central Index Key (CIK) is 784199. EDGAR lists every AORT filing under that number.
Ask anything about AORT
The research agent reads AORT's filings, financials, insider trades and 13F holders, then answers with sources.